Why Medicare Advantage plans need to improve memory care

Alzheimer’s disease alone currently costs Medicare Advantage (MA) plans $7.5 billion per year. With population aging and greater adoption of MA, that will rise to at least $15 billion (likely more) by 2030, even before accounting for new pharmaceutical innovations.

MA plans could reduce total spending on memory care patients by partnering with other stakeholders to improve patient management. Furthermore, partnering with other stakeholders to improve diagnosis could both bring down total spending and increase plan revenue due to higher patient risk scoring.